Page 129 - Read Online

Bogdos et al. Neuroimmunol Neuroinflammation 2018;5:19 I http://dx.doi.org/10.20517/2347-8659.2018.07 Page 5 of 5

Patient consent
Informed consent was obtained from the patient.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017;17:36.
2. Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R. Effects of anti-TNF
alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. Biomed Res Int
2014;2014:416892.
3. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid
arthritis. Arthritis Res Ther 2008;10:R45.
4. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving
anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 2014;16:R125.
5. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard
B, Asquier C, Martin A, Puechal X, Mariette X; Club Rhumatismes et Inflammation Section of the SFR. Pattern of demyelination
occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford) 2013;52:868-74.
6. Bosch X, Saiz A, Ramos-Casals M; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurologic disorders. Nat Rev
Neurol 2011;7:165-72.
7. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor
necrosis factor. Cytokine 2009;45:55-7.
8. Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha
inhibitors. Mult Scler 2011;17:1472-87.
9. Cereda CW, Zecca C, Mazzucchelli L, Valci L, Staedler C, Bassetti CL, Gobbi C. Tumefactive demyelinating lesions during etanercept
treatment requiring decompressive hemicraniectomy. Mult Scler 2013;19:820-3.
10. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory
disorders--what are the driving forces? Semin Cancer Biol 2014;24:61-70.
11. Kondo S, Tanimoto K, Yamada K, Yoshimoto G, Suematsu E, Fujisaki T, Oshiro Y, Tamura K, Takeshita M, Okamura S. Mature T/NK-
cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with
methotrexate. Virchows Arch 2013;462:399-407.
12. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, Nakatsuka S, Tamaru J, Iizuka A, Takeuchi T, Aozasa K.
Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J
Rheumatol 2007;34:322-31.
13. Fallah A, Sarfaraz B, Shanil E, John E. Paulseth, Paulseth JE, Jha NK. Case Series: tumefactive demyelinating lesions: a diagnostic
challenge. Can J Surg 2010;53:69-70.